Latest stories on ALT
Altimmune (ALT) Shares Fall Ahead of Pemvidutide Phase 2 Data Presentation
GuruFocus38 · neutralgeneral
Altimmune down after pemvidutide presentation in alcohol-use disorder
Seeking Alpha34 · bearishgeneral
Altimmune Says Data From Reclaim Phase 2 Trial To Be Presented At Tlm
The Fly56 · neutralproduct/pr
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
GlobeNewswire50 · neutralgeneral
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
StockTitan50 · neutralgeneral
Altimmune, Inc. (ALT) files 8-K
SEC 8-K50 · neutralgeneral
Altimmune, Inc. (ALT) files 8-K
SEC 8-K50 · neutralgeneral
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Business Insider58 · neutralproduct/pr
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Business Insider63 · neutralproduct/pr
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
GlobeNewswire63 · neutralproduct/pr
Altimmune management to meet with Truist
The Fly56 · neutralgeneral
Altimmune, Inc. (ALT) files 8-K
SEC 8-K50 · neutralgeneral
Altimmune price target lowered to $17 from $18 at Evercore ISI
The Fly42 · neutralanalyst
Altimmune to Participate in Stifel Cardiometabolic Forum
GlobeNewswire55 · neutralgeneral
Altimmune to Participate in Stifel Cardiometabolic Forum
Business Insider56 · neutralgeneral
Altimmune’s (ALT) Three Liver Trials Move Forward At Once
Yahoo Finance67 · bullishproduct/pr
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
StockTitan55 · neutralgeneral
Altimmune: Pemvidutide Performs, But A Long Wait Ahead
Seeking Alpha63 · neutralproduct/pr
Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning
Seeking Alpha59 · neutralproduct/pr
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Altimmune Q2 Earnings Call Highlights
Yahoo Finance56 · neutralearnings
Altimmune GAAP EPS of -$0.12 beats by $0.02
Seeking Alpha56 · neutralearnings